Login Register Cart 0
Generic placeholder image

Drug Delivery Letters

Editor-in-Chief

ISSN (Print): 2210-3031
ISSN (Online): 2210-304X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Advances in Orally Disintegrating Tablet: Properties, Formulation and Production

Author(s): Kar Ming Yee, Najwa Mohamad, Phei Er Kee, Yik-Ling Chew, Siew-Keah Lee, Vijayakumar Lakshminarayanan, Ching Siang Tan and Kai Bin Liew*

Volume 14, Issue 3, 2024

Published on: 20 March, 2024

Page: [211 - 225] Pages: 15

DOI: 10.2174/0122103031291909240317162755

Price: $65

Abstract

Healthcare practitioners, patients, and consumers widely recognize the convenience as-sociated with administering oral tablets. The emergence of orally disintegrating tablets (ODTs) represents a significant advancement in solid dosage forms, facilitating more convenient oral de-livery while maintaining medication safety, effectiveness, and quality. The ODTs market is ex-pected to experience continuous growth in the coming years despite the internal challenges faced by commercial manufacturers. This paper initiates a comprehensive discussion of the properties of ODTs, including palatability and taste, drug content, disintegration, mechanical strength, mois-ture content, safety, and efficacy. The formulation factors that affect each of these qualities are also discussed. Additionally, this review delves into the processes of the production of ODTs, en-compassing the approaches and technologies from the mixing of active ingredients and recipients to the formation and packaging of ODTs. This review provides valuable insights into the ad-vancement in ODTs technology, aiming to equip researchers with the knowledge necessary to improve quality and optimize efficiency, ultimately receiving high acceptance from patients or consumers.

« Previous Next »
[1]
Chauhan, B.S.; Chauhan, L.S.; Chatterjee, A.N.; Pandey, S.; Baghel, U.S. An approach based on advantages over conventional system. J Biomed Pharm Res, 2013, 2(1), 41-51.
[2]
Aparna, P.; Chandran, M.P.S.; Jaghatha, T.; Wesley, I.J.; Remya, B.S. A review on fast dissolving tablets. Indo Am J Pharm Sci, 2018, 05(04), 2412-2421.
[3]
Agiba, A.M.; Eldin, A.B. Insights into formulation technologies and novel strategies for the design of orally disintegrating dosage forms: A comprehensive industrial review. Int. J. Pharm. Pharm. Sci., 2019, 11(9), 8-20.
[http://dx.doi.org/10.22159/ijpps.2019v119.34828]
[4]
Kiniwa, R.; Miyake, M.; Kimura, S.; Itai, S.; Kondo, H.; Iwao, Y. Development of muco-adhesive orally disintegrating tablets containing tamarind gum-coated tea powders for oral care. Int. J. Pharm. X, 2019, 1(100012), 100012.
[http://dx.doi.org/10.1016/j.ijpx.2019.100012] [PMID: 31517277]
[5]
Dellon, E.S.; Lucendo, A.J.; Schlag, C.; Schoepfer, A.M.; Falk, G.W.; Eagle, G.; Nezamis, J.; Comer, G.M.; Knoop, K.; Hirano, I. Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: Randomized controlled trial. Clin. Gastroenterol. Hepatol., 2022, 20(11), 2485-2494.e15.
[http://dx.doi.org/10.1016/j.cgh.2022.02.013] [PMID: 35181572]
[6]
Tomita, T.; Yamaguchi, A.; Nishimura, N.; Goto, H.; Sumiya, K.; Arakawa, R.; Yoshida, T.; Tachiki, H.; Kohda, Y.; Kudo, K. Effect of food thickener and jelly wafer on the pharmacokinetics of levofloxacin orally disintegrating tablets. Heliyon, 2019, 5(11), e02764.
[http://dx.doi.org/10.1016/j.heliyon.2019.e02764] [PMID: 31844704]
[7]
AlHusban, F.; Perrie, Y.; Mohammed, A.R. Formulation of multiparticulate systems as lyophilised orally disintegrating tablets. Eur. J. Pharm. Biopharm., 2011, 79(3), 627-634.
[http://dx.doi.org/10.1016/j.ejpb.2011.05.014] [PMID: 21693189]
[8]
Desai, S.; Poddar, A.; Sawant, K. Formulation of cyclodextrin inclusion complex-based orally disintegrating tablet of eslicarbazepine acetate for improved oral bioavailability. Mater. Sci. Eng. C, 2016, 58, 826-834.
[http://dx.doi.org/10.1016/j.msec.2015.09.019] [PMID: 26478377]
[9]
Sugimori, E.; Kawasaki, Y. Cross-modal correspondence between visual information and taste perception of bitter foods and drinks. Food Qual. Prefer., 2022, 98, 104539.
[http://dx.doi.org/10.1016/j.foodqual.2022.104539]
[10]
Szejtli, J.; Szente, L. Elimination of bitter, disgusting tastes of drugs and foods by cyclodextrins. Eur. J. Pharm. Biopharm., 2005, 61(3), 115-125.
[http://dx.doi.org/10.1016/j.ejpb.2005.05.006] [PMID: 16185857]
[11]
Gopinath, R.; Naidu, R.A.S.; Soujanya, V. Oral disintegrating tablets: A current review. Int J Pharm Biol Sci Arch, 2013, 4(6), 1134-1154.
[12]
Hayakawa, Y.; Uchida, S.; Namiki, N. Evaluation of the ease of taking mini-tablets compared with other tablet formulations in healthy volunteers. Eur. J. Pharm. Sci., 2016, 84, 157-161.
[http://dx.doi.org/10.1016/j.ejps.2015.12.029] [PMID: 26739235]
[13]
Hellberg, E.; Westberg, A.; Appelblad, P.; Mattsson, S. Evaluation of dissolution techniques for orally disintegrating mini-tablets. J. Drug Deliv. Sci. Technol., 2021, 61, 102191.
[http://dx.doi.org/10.1016/j.jddst.2020.102191]
[14]
Loratadine, O.D.T. In: The pharmocopeia of the United States of America 43 ed; Rockville; M.D. The United States Pharmocopeial Convention, 2020; 2, pp. 2678-2679.
[15]
Olanzapine, O.D.T. In: The pharmocopeia of the United States of America 43 ed; Rockville; M.D. The United States Pharmocopeial Convention, 2020; 2, p. 3240.
[16]
Ondansetron, O.D.T. In: The pharmocopeia of the United States of America, 43 ed; Rockville; M.D. The United States Pharmocopeial Convention, 2020; 2, p. 3271.
[17]
Abdelbary, G.; Eouani, C.; Prinderre, P.; Joachim, J.; Reynier, J.; Piccerelle, P. Determination of the in vitro disintegration profile of rapidly disintegrating tablets and correlation with oral disintegration. Int. J. Pharm., 2005, 292(1-2), 29-41.
[http://dx.doi.org/10.1016/j.ijpharm.2004.08.019] [PMID: 15725551]
[18]
Brniak, W.; Jachowicz, R.; Pelka, P. The practical approach to the evaluation of methods used to determine the disintegration time of orally disintegrating tablets (ODTs). Saudi Pharm. J., 2015, 23(4), 437-443.
[http://dx.doi.org/10.1016/j.jsps.2015.01.015] [PMID: 27134547]
[19]
Hooper, P.; Lasher, J.; Alexander, K.S.; Baki, G. A new modified wetting test and an alternative disintegration test for orally disintegrating tablets. J. Pharm. Biomed. Anal., 2016, 120, 391-396.
[http://dx.doi.org/10.1016/j.jpba.2015.12.046] [PMID: 26774944]
[20]
Yu, J.; Shan, X.; Chen, S.; Sun, X.; Song, P.; Zhao, R.; Hu, L. Preparation and evaluation of novel multi-channel orally disintegrating tablets. Eur. J. Pharm. Sci., 2020, 142, 105108.
[http://dx.doi.org/10.1016/j.ejps.2019.105108] [PMID: 31669391]
[21]
Szakonyi, G.; Zelkó, R. Prediction of oral disintegration time of fast disintegrating tablets using texture analyzer and computational optimization. Int. J. Pharm., 2013, 448(2), 346-353.
[http://dx.doi.org/10.1016/j.ijpharm.2013.03.047] [PMID: 23558313]
[22]
Khan, A.; Iqbal, Z.; Ibrahim, M.; Nasir, F.; Ullah, Z. Prediction of the effect of taste masking on disintegration behavior, mechanical strength and rheological characteristics of highly water soluble drug (itopride HCl); an application of SeDeM-ODT expert system. Powder Technol., 2015, 284, 411-417.
[http://dx.doi.org/10.1016/j.powtec.2015.06.062]
[23]
Vanbillemont, B.; Everaert, H.; De Beer, T. New advances in the characterization of lyophilised orally disintegrating tablets. Int. J. Pharm., 2020, 579, 119153.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119153] [PMID: 32084575]
[24]
Kokott, M.; Lura, A.; Breitkreutz, J.; Wiedey, R. Evaluation of two novel co-processed excipients for direct compression of orodispersible tablets and mini-tablets. Eur. J. Pharm. Biopharm., 2021, 168, 122-130.
[http://dx.doi.org/10.1016/j.ejpb.2021.08.016] [PMID: 34474110]
[25]
Kadota, K.; Terada, H.; Fujimoto, A.; Nogami, S.; Uchiyama, H.; Tozuka, Y. Formulation and evaluation of bitter taste-masked orally disintegrating tablets of high memantine hydrochloride loaded granules coated with polymer via layering technique. Int. J. Pharm., 2021, 604, 120725.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120725] [PMID: 34029663]
[26]
Veronica, N.; Liew, C.V.; Heng, P.W.S. Insights on the role of excipients and tablet matrix porosity on aspirin stability. Int. J. Pharm., 2020, 580, 119218.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119218] [PMID: 32165224]
[27]
Neelima, A.; Shreya, T.; Manju, M. Formulation of olanzapine nanosuspension based orally disintegrating tablets (ODT); comparative evaluation of lyophilization and electrospraying process as solidification techniques. Adv. Powder Technol., 2018, 29(8), 1913-1924.
[28]
Senem, S.Ö.; İmran, V. Advantages and quality control of orally disintegrating tablets. FABAD J. Pharm Sci, 2009, 34, 167-172.
[29]
Walsh, J.; Cram, A.; Woertz, K.; Breitkreutz, J.; Winzenburg, G.; Turner, R.; Tuleu, C. Playing hide and seek with poorly tasting paediatric medicines: Do not forget the excipients. Adv. Drug Deliv. Rev., 2014, 73, 14-33.
[http://dx.doi.org/10.1016/j.addr.2014.02.012] [PMID: 24614069]
[30]
Srdjenovic, B.; Torovic, L.; Kladar, N.; Bozin, B.; Sudji, J. Health risk assessment for pediatric population associated with ethanol and selected residual solvents in herbal based products. Regul. Toxicol. Pharmacol., 2019, 107, 104406.
[http://dx.doi.org/10.1016/j.yrtph.2019.104406] [PMID: 31238087]
[31]
Alves Filho, E.G.; Silva, L.M.A.; Araújo, N.V.P.; Alves, E.G.; Lião, L.M.; Alcantara, G.B.; Luciano, M.L.; Glaucia, B.A. Qualitative and quantitative control of pediatric syrups using Nuclear Magnetic Resonance and chemometrics. J. Pharm. Biomed. Anal., 2018, 153, 29-36.
[http://dx.doi.org/10.1016/j.jpba.2018.02.013] [PMID: 29459233]
[32]
Khan, D.; Kirby, D.; Bryson, S.; Shah, M.; Rahman Mohammed, A. Paediatric specific dosage forms: Patient and formulation considerations. Int. J. Pharm., 2022, 616, 121501.
[http://dx.doi.org/10.1016/j.ijpharm.2022.121501] [PMID: 35092832]
[33]
Pawar, H.; Varkhade, C.; Jadhav, P.; Mehra, K. Development and evaluation of orodispersible tablets using a natural polysaccharide isolated from Cassia tora seeds. Integr. Med. Res., 2014, 3(2), 91-98.
[http://dx.doi.org/10.1016/j.imr.2014.03.002] [PMID: 28664083]
[34]
Anttila, S.A.K.; Leinonen, E.V.J. A review of the pharmacological and clinical profile of mirtazapine. CNS Drug Rev., 2001, 7(3), 249-264.
[http://dx.doi.org/10.1111/j.1527-3458.2001.tb00198.x] [PMID: 11607047]
[35]
Rai, P.K.; Modi, J. Orally disintegrating tablets: A novel approach for medication. Int J Med Health Res, 2019, 5(1), 84-91.
[36]
Laffleur, F.; Keckeis, V. WITHDRAWN: Advances in drug delivery systems: Work in progress still needed? Int. J. Pharm. X, 2020, 2, 100050.
[http://dx.doi.org/10.1016/j.ijpx.2020.100050] [PMID: 32577616]
[37]
Armando, Y.P.; Schramm, S.G.; de Freitas Silva, M.; Kano, E.K.; Koono, E.E.M.; Porta, V.; dos Reis Serra, C.H. Bioequivalence assay between orally disintegrating and conventional tablet formulations in healthy volunteers. Int. J. Pharm., 2009, 366(1-2), 149-153.
[http://dx.doi.org/10.1016/j.ijpharm.2008.09.021] [PMID: 18848869]
[38]
Kambayashi, A.; Kiyota, T. A physiologically-based drug absorption modeling for orally disintegrating tablets. Eur. J. Pharm. Biopharm., 2020, 152, 1-9.
[http://dx.doi.org/10.1016/j.ejpb.2020.04.018] [PMID: 32371153]
[39]
Chen, L.; Jiang, X.; Huang, L.; Lan, K.; Wang, H.; Hu, L.; Ren, J.; Li, X.; Zou, Q. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: A randomized sequence, open-label, two-way crossover study. Clin. Ther., 2009, 31(10), 2242-2248.
[http://dx.doi.org/10.1016/j.clinthera.2009.09.015] [PMID: 19922895]
[40]
Madhura, D.; Umesh, N.; Amol, P. Preparation of Cefpodoxime Proxetil: Polymeric microspheres by the emulsion solvent diffusion method for taste masking. Int. J. Pharm. Tech. Res., 2011, 3(1), 411-419.
[41]
Nakano, Y.; Maeda, A.; Uchida, S.; Namiki, N. Preparation and evaluation of unpleasant taste-masked pioglitazone orally disintegrating tablets. Int. J. Pharm., 2013, 446(1-2), 160-165.
[http://dx.doi.org/10.1016/j.ijpharm.2013.02.019] [PMID: 23419665]
[42]
Reddy, M.S.; Rao, N.G.R.; Krishna, D. Formulation and design of taste masked quetiapine fumarate orally fast disintegrating tablet. Asian J Pharm Clin, 2013, 6(2), 70-75.
[43]
Wang, C.; Hu, S.; Sun, C.C. Expedited development of a high dose orally disintegrating metformin tablet enabled by sweet salt formation with acesulfame. Int. J. Pharm., 2017, 532(1), 435-443.
[http://dx.doi.org/10.1016/j.ijpharm.2017.08.100] [PMID: 28844896]
[44]
Abd El Rasoul, S.; Shazly, G.A. Propafenone HCl fast dissolving tablets containing subliming agent prepared by direct compression method. Saudi Pharm. J., 2017, 25(7), 1086-1092.
[http://dx.doi.org/10.1016/j.jsps.2017.05.003] [PMID: 29158720]
[45]
Robino, A.; Rosso, N.; Guerra, M.; Corleone, P.; Casagranda, B.; Giraudi, P.J.; Tiribelli, C.; Simeth, C.; Monica, F.; La Bianca, M.; Gasparini, P.; de Manzini, N.; Palmisano, S.; Nicolò, M.; Silvia, P. Taste perception and expression in stomach of bitter taste receptor tas2r38 in obese and lean subjects. Appetite, 2021, 166, 105595.
[http://dx.doi.org/10.1016/j.appet.2021.105595] [PMID: 34242732]
[46]
Bayoumi, A.A. Formulation, optimization, and evaluation of sitagliptin and simvastatin rapidly dissolving tablets. Intern. J. Appl. Pharma., 2018, 10(5), 270-273.
[http://dx.doi.org/10.22159/ijap.2018v10i5.28122]
[47]
Ibrahim, M.A.; Abou El Ela, A.E.S.F.; Ela, A.E.S.F. Optimized furosemide taste masked orally disintegrating tablets. Saudi Pharm. J., 2017, 25(7), 1055-1062.
[http://dx.doi.org/10.1016/j.jsps.2017.04.002] [PMID: 29158715]
[48]
Takeuchi, Y.; Umemura, K.; Tahara, K.; Takeuchi, H. Formulation design of hydroxypropyl cellulose films for use as orally disintegrating dosage forms. J. Drug Deliv. Sci. Technol., 2018, 46, 93-100.
[http://dx.doi.org/10.1016/j.jddst.2018.05.002]
[49]
Nishiyama, T.; Ogata, T.; Ozeki, T. Preparation of bitter taste-masking granules of lafutidine for orally disintegrating tablets using water-insoluble/soluble polymer combinations. J. Drug Deliv. Sci. Technol., 2016, 32, 38-42.
[http://dx.doi.org/10.1016/j.jddst.2016.01.005]
[50]
Anraku, M.; Mizukai, Y.; Maezaki, Y.; Kawano, K.; Okazaki, S.; Takeshita, K.; Adachi, T.; Otagiri, M.; Iohara, D.; Hirayama, F. The preparation and validation of chitosan tablets that rapidly disperse and disintegrate as an oral adsorbent in the treatment of lifestyle-related diseases. Carbohydr. Polym., 2021, 253, 117246.
[http://dx.doi.org/10.1016/j.carbpol.2020.117246] [PMID: 33279001]
[51]
Rane, S.S.; Hamed, E.; Rieschl, S. An exact model for predicting tablet and blend content uniformity based on the theory of fluctuations in mixtures. J. Pharm. Sci., 2012, 101(12), 4501-4515.
[http://dx.doi.org/10.1002/jps.23313] [PMID: 22987282]
[52]
Jain, A.K.; Kakde, A.; Jain, C.P.; Meena, M.K.; Gaur, K. Effect of combination of surfactant and super disintegrating agent on invitro disintegration and dissolution release profile of medroxyprogestrone acetate tablet. Int J Pharm Clin Res, 2010, 2(1), 36-39.
[53]
Alalaiwe, A.; Fayed, M.H.; Alshahrani, S.M.; Alsulays, B.B.; Alshetaili, A.S.; Tawfeek, H.M.; Khafagy, E.S. Application of design of experiment approach for investigating the effect of partially pre-gelatinized starch on critical quality attributes of rapid orally disintegrating tablets. J. Drug Deliv. Sci. Technol., 2019, 49, 227-234.
[http://dx.doi.org/10.1016/j.jddst.2018.11.018]
[54]
Mahrous, G.M.; Kassem, M.G.; Ibrahim, M.A.; Auda, S.H. Formulation and evaluation of orally disintegrating clopidogrel tablets. Braz. J. Pharm. Sci., 2016, 52(2), 309-318.
[http://dx.doi.org/10.1590/S1984-82502016000200009]
[55]
Ajit Shankarrao, K.; Dhairysheel Mahadeo, G.; Pankaj Balavantrao, K. Formulation and in-vitro evaluation of orally disintegrating tablets of olanzapine-2-hydroxypropyl-β-cyclodextrin inclusion complex. Iran. J. Pharm. Res., 2010, 9(4), 335-347.
[PMID: 24381598]
[56]
Olah, I.; Lasher, J.; Regdon, G., Jr; Pintye-Hodi, K.; Baki, G.; Sovany, T. Evaluating superdisintegrants for their performance in orally disintegrating tablets containing lysozyme enzyme. J. Drug Deliv. Sci. Technol., 2019, 49, 396-404.
[http://dx.doi.org/10.1016/j.jddst.2018.12.012]
[57]
Reddy, K.R.; Jaya, S.; Srikanth, R.; Madhu, C. Formulation and evaluation of lamotrizine orodispersible Tablets. Indo Am J Pharm Sci, 2018, 05(01), 769-778.
[58]
Aswathy, K.N.; Asdaq, S.M.B.; Saritha, C.K.; Thomas, L.; Haridas, N.; Viswanad, V.; Sahu, R.K.; Fattepur, S.; Alamri, A.S.; Alsanie, W.F.; Alhomrani, M.; Sreeharsha, N.; Khalid Anwer, M. Formulation and in-vitro characterization of fast-disintegrating herbal extract sublingual immunotherapy tablet for peanut-induced allergic asthma. Saudi J. Biol. Sci., 2022, 29(3), 1283-1297.
[http://dx.doi.org/10.1016/j.sjbs.2021.12.031] [PMID: 35280568]
[59]
Reddy, K.R.; Jaya, S.; Himani, K.; Madhu, C. Formulation and evaluation of ceruroxime axetil orodispersible tablets. Indo Am J Pharm Sci, 2018, 05(01), 745-754.
[60]
Khan, H.U.; Hanif, M.; Sarfraz, R.M.; Maheen, S.; Afzal, S.; Sher, M.; Afzal, K.; Mahmood, A.; Shamim, A. Development and evaluation of novel antihypertensive orodispersible tablets. Pak. J. Pharm. Sci., 2017, 30(5), 1557-1565.
[PMID: 29084673]
[61]
Kumar, Y.; Chouke, R.; Jain, S.; Shukla, K. Design, Development and evaluation of orodispersible tablet of serotonin 5HT3 receptor antagonists drug. Int J Pharm Sci Med, 2019, 4(10), 15-50.
[62]
Nagar, M.; Yadav, A.V. Cinnarizine orodispersible tablet: A chitosan based fast mouth dissolving technology. Int. J. Pharm. Tech. Res., 2009, 1(4), 1079-1091.
[63]
Gottumukkala, M.V.; Kumar, K.S.; Ahmed, M.G.; Krishna, K. An approach to formulate and evaluate labetolol as fast dissolving tablets. World J. Pharm. Res., 2014, 3(6), 735-754.
[64]
Kannaiah, J.; Rao, J.P.; Kotaiah, M.R.; Babu, G.R. Formulation and evaluation of metformin immediate release tablet. Indo Am J Pharm Sci, 2014, 1(4), 209-218.
[65]
Goyanes, A.; Souto, C.; Martínez-Pacheco, R. Co-processed MCC-Eudragit® E excipients for extrusion–spheronization. Eur. J. Pharm. Biopharm., 2011, 79(3), 658-663.
[http://dx.doi.org/10.1016/j.ejpb.2011.07.013] [PMID: 21827853]
[66]
Maclean, N.; Walsh, E.; Soundaranathan, M.; Khadra, I.; Mann, J.; Williams, H.; Markl, D. Exploring the performance-controlling tablet disintegration mechanisms for direct compression formulations. Int. J. Pharm., 2021, 599, 120221.
[http://dx.doi.org/10.1016/j.ijpharm.2021.120221] [PMID: 33540006]
[67]
Patel, N.S.; Patel, V.M.; Patel, K.A.; Modasiya, K.M. Development and evaluation of fast dissolving tablets of flurbiprofen. J Club for Pharm Sci, 2014, 1(1), 76-86.
[68]
Debotton, N.; Dahan, A. Applications of polymers as pharmaceutical excipients in solid oral dosage forms. Med. Res. Rev., 2016, 1-46.
[PMID: 27502146]
[69]
Lal, M.; Lai, M.; Estrada, M.; Zhu, C. Developing a flexible pediatric dosage form for antiretroviral therapy: A fast-dissolving tablet. J. Pharm. Sci., 2017, 106(8), 2173-2177.
[http://dx.doi.org/10.1016/j.xphs.2017.05.004] [PMID: 28499879]
[70]
Ali, J.; Zgair, A.; Hameed, G.S.; Garnett, M.C.; Roberts, C.J.; Burley, J.C.; Gershkovich, P. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine. Int. J. Pharm., 2019, 555, 228-236.
[http://dx.doi.org/10.1016/j.ijpharm.2018.11.051] [PMID: 30465852]
[71]
Saharan, V.A.; Kukkar, V.; Kataria, M.; Gera, M.; Choudhury, P.K. Dissolution enhancement of drugs part I: Technologies and effect of carriers. Int J Health Res, 2009, 2(2), 107-124.
[72]
Lai, F.; Pini, E.; Corrias, F.; Perricci, J.; Manconi, M.; Fadda, A.M.; Sinico, C. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying. Int. J. Pharm., 2014, 467(1-2), 27-33.
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.047] [PMID: 24680963]
[73]
Assaf, S.M.; Qandil, A.M.; Al-Ani, E.A. Fast and pH-dependent release of domperidone from orally disintegrating tablets. Pharm. Dev. Technol., 2010, 1-9.
[PMID: 22304659]
[74]
Khan, S.I.; Navya, B.; Kumar, C.; Reddy, Y.K.; Rao, K.N.V.; Dutt, K.R. Formulation, optimization and evaluation of caffeine effervescent tablets. Indo Am J Pharm Sci, 2018, 05(04), 2222-2229.
[75]
Kumar, J.N.S.; Gunda, R.K. Design, formulation and evaluation of pravastatin fast dissolving tablets. Pharm. Methods, 2018, 9(1), 15-22.
[76]
Stevens, H.; Voelker, M.; Gow, L.; MacDougall, F.; Bieri, G. In-vivo disintegration and absorption of two fast acting aspirin tablet formulations compared to ibuprofen tablets using pharmacoscintigraphy. J. Drug Deliv. Sci. Technol., 2019, 51, 535-541.
[http://dx.doi.org/10.1016/j.jddst.2019.02.027]
[77]
Kambayashi, A.; Sako, K.; Kondo, H. Characterization of the buccal and gastric transit of orally disintegrating tablets in humans using gamma scintigraphy. Int. J. Pharm., 2020, 576, 118937.
[http://dx.doi.org/10.1016/j.ijpharm.2019.118937] [PMID: 31816352]
[78]
He, X.; Secreast, P.J.; Amidon, G.E. Mechanistic study of the effect of roller compaction and lubricant on tablet mechanical strength. J. Pharm. Sci., 2007, 96(5), 1342-1355.
[http://dx.doi.org/10.1002/jps.20938] [PMID: 17455360]
[79]
Zayed, G.; Ibrahim, M.A.; Alshora, D.H.; El-Garhy, O.H.; Kamal, I.; Amin, M.A.; Bakr, A.G.; Ali, F.E.M. Novel water-soluble lubricant for the preparation of tiemonium methylsulfate fast-dissolving tablets. J. Drug Deliv. Sci. Technol., 2020, 60, 102031.
[http://dx.doi.org/10.1016/j.jddst.2020.102031]
[80]
Tranová, T.; Macho, O.; Loskot, J.; Mužíková, J. Study of rheological and tableting properties of lubricated mixtures of co-processed dry binders for orally disintegrating tablets. Eur. J. Pharm. Sci., 2022, 168, 106035.
[http://dx.doi.org/10.1016/j.ejps.2021.106035] [PMID: 34634469]
[81]
Vanbillemont, B.; De Beer, T. Application of polyvinyl acetate in an innovative formulation strategy for lyophilized orally disintegrating tablets. Int. J. Pharm., 2020, 588, 119717.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119717] [PMID: 32771503]
[82]
Arvapalli, S.; Shyamala, S. Oral disintegration tablets: An updated review Indo Am J P Sci., 2019, 6(3)
[83]
Khemchand, G.; Indrajeet, S. Formulation and evaluation of orally disintegrating tablets of antihypertensive drug naftopidil. Asian J Pharm Res, 2015, 3(1), 1-7.
[84]
Venkateswarlu, K.; Jami, K.P. Formulation development and in vitro evaluation of mouth dissolving tablets of pioglitazone hydrochloride. PharmaTutor, 2016, 4(12), 37-42.
[85]
Okuda, Y.; Irisawa, Y.; Okimoto, K.; Osawa, T.; Yamashita, S. A new formulation for orally disintegrating tablets using a suspension spray-coating method. Int. J. Pharm., 2009, 382(1-2), 80-87.
[http://dx.doi.org/10.1016/j.ijpharm.2009.08.010] [PMID: 19686825]
[86]
Okuda, Y.; Irisawa, Y.; Okimoto, K.; Osawa, T.; Yamashita, S. Further improvement of orally disintegrating tablets using micronized ethylcellulose. Int. J. Pharm., 2012, 423(2), 351-359.
[http://dx.doi.org/10.1016/j.ijpharm.2011.10.050] [PMID: 22138608]
[87]
Sakure, K.; Kumari, L.; Badwaik, H. Development and evaluation of solid dispersion based rapid disintegrating tablets of poorly water-soluble anti-diabetic drug. J. Drug Deliv. Sci. Technol., 2020, 60, 101942.
[http://dx.doi.org/10.1016/j.jddst.2020.101942]
[88]
Maheshwar, M. Phytochemical screening and TLC fingerprinting formulation and evaluation of fast disintegrating tablets of fenofibrate. Indo Am J Pharm Sci, 2018, 05(01), 318-325.
[89]
Liu, R.; Li, L.; Yin, W.; Xu, D.; Zang, H. Near-infrared spectroscopy monitoring and control of the fluidized bed granulation and coating processes—A review. Int. J. Pharm., 2017, 530(1-2), 308-315.
[http://dx.doi.org/10.1016/j.ijpharm.2017.07.051] [PMID: 28743552]
[90]
Wagner-Hattler, L.; Wyss, K.; Schoelkopf, J.; Huwyler, J.; Puchkov, M. In vitro characterization and mouthfeel study of functionalized calcium carbonate in orally disintegrating tablets. Int. J. Pharm., 2017, 534(1-2), 50-59.
[http://dx.doi.org/10.1016/j.ijpharm.2017.10.009] [PMID: 28987455]
[91]
Wang, C.; Sun, C.C. The efficient development of a sildenafil orally disintegrating tablet using a material sparing and expedited approach. Int. J. Pharm., 2020, 589, 119816.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119816] [PMID: 32877727]
[92]
Usmani, M.T.; Shoaib, M.H.; Nasiri, M.I.; Yousuf, R.I.; Zaheer, K.; Ahmed, K. Development and evaluation of orally disintegrating tablets of Montelukast Sodium by direct compression method. Trop. J. Pharm. Res., 2015, 14(1), 1-6.
[http://dx.doi.org/10.4314/tjpr.v14i1.1]
[93]
Shivappa, N.N.; Rajan, D.W.; Krishna, R.S.; Gaikwad, V. Formulation and evaluation of furosemide oral disintegrating tablets. Int J Pharm Sci Invent, 2018, 7(6-1), 1-10.
[94]
Chaudhary, S.A.; Chaudhary, A.B.; Mehta, T.A. Excipients updates for orally disintegrating dosage forms. Int. J. Res. Pharm., 2010, 1(2), 103-107.
[95]
Katsuno, E.; Tahara, K.; Takeuchi, Y.; Takeuchi, H. Orally disintegrating tablets prepared by a co-processed mixture of micronized crospovidone and mannitol using a ball mill to improve compactibility and tablet stability. Powder Technol., 2013, 241, 60-66.
[http://dx.doi.org/10.1016/j.powtec.2013.03.008]
[96]
Akdag, Y.; Gulsun, T.; Izat, N.; Cetin, M.; Oner, L.; Sahin, S. Characterization and comparison of deferasirox fast disintegrating tablets prepared by direct compression and lyophilization methods. J. Drug Deliv. Sci. Technol., 2020, 57, 101760.
[http://dx.doi.org/10.1016/j.jddst.2020.101760]
[97]
Gulsun, T.; Akdag Cayli, Y.; Izat, N.; Cetin, M.; Oner, L.; Sahin, S. Development and evaluation of terbutaline sulfate orally disintegrating tablets by direct compression and freeze drying methods. J. Drug Deliv. Sci. Technol., 2018, 46, 251-258.
[http://dx.doi.org/10.1016/j.jddst.2018.05.014]
[98]
Türkmen, Ö.; Ay Şenyiğit, Z.; Baloğlu, E. Formulation and evaluation of fexofenadine hydrochloride orally disintegrating tablets for pediatric use. J. Drug Deliv. Sci. Technol., 2018, 43, 201-210.
[http://dx.doi.org/10.1016/j.jddst.2017.10.008]
[99]
Güncan, G.; Yeğen, G.; Mesut, B.; Aksu, B.; Özsoy, Y. Formulation design of the oral disintegrating tablets including alfuzosin hydrochloride with risk evaluation via quality by design. ACTA Pharmaceutica Sciencia, 2017, 55(2), 57-76.
[http://dx.doi.org/10.23893/1307-2080.APS.05512]
[100]
Winarti, L.; Ameliana, L.; Nurahmanto, D. Formula optimization of orally disintegrating tablet containing meloxicam nanoparticles. Indones. J. Pharm., 2017, 28(1), 53-64.
[http://dx.doi.org/10.14499/indonesianjpharm28iss1pp53]
[101]
Tanimura, S.; Tahara, K.; Takeuchi, H. Spray-dried composite particles of erythritol and porous silica for orally disintegrating tablets prepared by direct tableting. Powder Technol., 2015, 286, 444-450.
[http://dx.doi.org/10.1016/j.powtec.2015.08.011]
[102]
Kim, J.I.; Cho, S.M.; Cui, J.H.; Cao, Q.R.; Oh, E.; Lee, B.J. In vitro and in vivo correlation of disintegration and bitter taste masking using orally disintegrating tablet containing ion exchange resin-drug complex. Int. J. Pharm., 2013, 455(1-2), 31-39.
[http://dx.doi.org/10.1016/j.ijpharm.2013.07.072] [PMID: 23933050]
[103]
Stange, U.; Führling, C.; Gieseler, H. Formulation, preparation, and evaluation of novel orally disintegrating tablets containing taste-masked naproxen sodium granules and naratriptan hydrochloride. J. Pharm. Sci., 2014, 103(4), 1233-1245.
[http://dx.doi.org/10.1002/jps.23896] [PMID: 24532095]
[104]
Liew, K.B.; Odeniyi, M.A.; Peh, K.K. Application of freeze-drying technology in manufacturing orally disintegrating films. Pharm. Dev. Technol., 2016, 21(3), 346-353.
[http://dx.doi.org/10.3109/10837450.2014.1003657] [PMID: 25597618]
[105]
Al Ashmawy, A.Z.G.; Eissa, N.G.; El Nahas, H.M.; Balata, G.F. Fast disintegrating tablet of Doxazosin Mesylate nanosuspension: Preparation and characterization. J. Drug Deliv. Sci. Technol., 2021, 61, 102210.
[http://dx.doi.org/10.1016/j.jddst.2020.102210]
[106]
Amelian, A.; Wasilewska, K.; Wesoły, M.; Ciosek-Skibińska, P.; Winnicka, K. Taste-masking assessment of orally disintegrating tablets and lyophilisates with cetirizine dihydrochloride microparticles. Saudi Pharm. J., 2017, 25(8), 1144-1150.
[http://dx.doi.org/10.1016/j.jsps.2017.06.001] [PMID: 30166902]
[107]
Morott, J.T.; Pimparade, M.; Park, J.B.; Worley, C.P.; Majumdar, S.; Lian, Z.; Pinto, E.; Bi, Y.; Durig, T.; Repka, M.A. The effects of screw configuration and polymeric carriers on hot-melt extruded taste-masked formulations incorporated into orally disintegrating tablets. J. Pharm. Sci., 2015, 104(1), 124-134.
[http://dx.doi.org/10.1002/jps.24262] [PMID: 25410968]
[108]
Venkateswarlu, K.; Naikl, S.B.T.; Chandrasekhar, K.B. Formulation and in-vitro evaluation of orlistat orodispersible tablets for enhancement of dissolution rate. Int. J. Pharm. Pharm. Sci., 2016, 8(4), 236-241.
[109]
Abdelbary, G.; Prinderre, P.; Eouani, C.; Joachim, J.; Reynier, J.P.; Piccerelle, P. The preparation of orally disintegrating tablets using a hydrophilic waxy binder. Int. J. Pharm., 2004, 278(2), 423-433.
[http://dx.doi.org/10.1016/j.ijpharm.2004.03.023] [PMID: 15196646]
[110]
Alshehri, S.M.; Park, J.B.; Alsulays, B.B.; Tiwari, R.V.; Almutairy, B.; Alshetaili, A.S.; Morott, J.; Shah, S.; Kulkarni, V.; Majumdar, S.; Martin, S.T.; Mishra, S.; Wang, L.; Repka, M.A. Mefenamic acid taste-masked oral disintegrating tablets with enhanced solubility via molecular interaction produced by hot melt extrusion technology. J. Drug Deliv. Sci. Technol., 2015, 27, 18-27.
[http://dx.doi.org/10.1016/j.jddst.2015.03.003] [PMID: 25914727]
[111]
Gryczke, A.; Schminke, S.; Maniruzzaman, M.; Beck, J.; Douroumis, D. Development and evaluation of orally disintegrating tablets (ODTs) containing Ibuprofen granules prepared by hot melt extrusion. Colloids Surf. B Biointerfaces, 2011, 86(2), 275-284.
[http://dx.doi.org/10.1016/j.colsurfb.2011.04.007] [PMID: 21592751]
[112]
Xu, Y.; Yan, G.; Wen, X.; Wu, L.; Deng, R.; Liang, Q.; Zhang, L.; Chen, H.; Feng, X.; He, J. Preparation, evaluation, and pharmacokinetics in beagle dogs of a taste-masked flunixin meglumine orally disintegrating tablet prepared using hot-melt extrusion technology and D-optimal mixture design. Eur. J. Pharm. Sci., 2022, 168, 106019.
[http://dx.doi.org/10.1016/j.ejps.2021.106019] [PMID: 34563655]
[113]
Dauer, K.; Werner, C.; Lindenblatt, D.; Wagner, K.G. Impact of process stress on protein stability in highly-loaded solid protein/PEG formulations from small-scale melt extrusion. Int. J. Pharm. X, 2023, 5, 100154.
[http://dx.doi.org/10.1016/j.ijpx.2022.100154] [PMID: 36632069]
[114]
Ha, Y.L.; Suji, R.; Han, S.Y.; Yoo, N.J.; Minki, J.; Cheong-Weon, C.; Jong-Suep, B. Enhanced antioxidant and anti-inflammatory effects of bee pollen and honey hybrid formulation by hot-melt extrusion. Food Hydrocoll., 2023, 110167.
[115]
Fina, F.; Madla, C.M.; Goyanes, A.; Zhang, J.; Gaisford, S.; Basit, A.W. Fabricating 3D printed orally disintegrating printlets using selective laser sintering. Int. J. Pharm., 2018, 541(1-2), 101-107.
[http://dx.doi.org/10.1016/j.ijpharm.2018.02.015] [PMID: 29454028]
[116]
Dave, V.; Yadav, R.B.; Ahuja, R.; Yadav, S. Formulation design and optimization of novel fast dissolving tablet of chlorpheniramine maleate by using lyophilization techniques. Bull. Fac. Pharm. Cairo Univ., 2017, 55(1), 31-39.
[http://dx.doi.org/10.1016/j.bfopcu.2016.12.001]
[117]
Huanbutta, K.; Yunsir, A.; Sriamornsak, P.; Sangnim, T. Development and in vitro/in vivo evaluation of tamarind seed gum-based oral disintegrating tablets after fabrication by freeze drying. J. Drug Deliv. Sci. Technol., 2019, 54, 101298.
[http://dx.doi.org/10.1016/j.jddst.2019.101298]
[118]
Song, H.; Moon, C.; Lee, B.J.; Oh, E. Mesoporous pravastatin solid dispersion granules incorporable into orally disintegrating tablets. J. Pharm. Sci., 2018, 107(7), 1886-1895.
[http://dx.doi.org/10.1016/j.xphs.2018.03.003] [PMID: 29530714]
[119]
Pathan, I.B.; Shingare, P.R.; Kurumkar, P. Formulation design and optimization of novel mouth dissolving tablets for venlafaxine hydrochloride using sublimation technique. J. Pharm. Res., 2013, 6(6), 593-598.
[http://dx.doi.org/10.1016/j.jopr.2013.04.054]
[120]
Mostafa, M.; Gardouh, A.R.; Abogresha, N.M.; Gad, S. Factorial design, formulation, in vitro and in vivo evaluation of rapid orally disintegrating tablets prepared by sublimation technique using captopril as a model drug. J. Drug Deliv. Sci. Technol., 2020, 57(101635), 101635.
[http://dx.doi.org/10.1016/j.jddst.2020.101635]
[121]
Sasidhar, R.L.C.; Vidyadhara, S.; Balakrishna, T.; Vijetha, K.; Kasaiah, V. Development and evaluation of paroxetine hydrochloride fast dissolving tablets. Indo Am J Pharm Sci, 2014, 1(2), 90-97.
[122]
Kshirasagar, N.; Malvey, S.; Kumar, K.S.; Vijaya, C.; Reddy, M.V. Formulation and evaluation of orodipsersible tablet of naratriptan using sublimation technique. Indo Am J Pharm Sci, 2016, 3(1), 22-30.
[123]
Kumar, R.; Patil, M.B.; Patil, S.R.; Paschapur, M.S. Mahalaxmi. Development and characterization of orodispersible tablets of aceclofenac by sublimation technique. Int. J. Pharm. Tech. Res., 2009, 1(2), 210-214.
[124]
Sano, S.; Iwao, Y.; Noguchi, S.; Kimura, S.; Itai, S. Design and evaluation of microwave-treated orally disintegrating tablets containing polymeric disintegrant and mannitol. Int. J. Pharm., 2013, 448(1), 132-141.
[http://dx.doi.org/10.1016/j.ijpharm.2013.03.023] [PMID: 23524122]
[125]
Sano, S.; Iwao, Y.; Kimura, S.; Noguchi, S.; Itai, S. Impact of active ingredients on the swelling properties of orally disintegrating tablets prepared by microwave treatment. Int. J. Pharm., 2014, 468(1-2), 234-242.
[http://dx.doi.org/10.1016/j.ijpharm.2014.04.011] [PMID: 24709215]
[126]
Kuno, Y.; Kojima, M.; Nakagami, H.; Yonemochi, E.; Terada, K. Effect of the type of lubricant on the characteristics of orally disintegrating tablets manufactured using the phase transition of sugar alcohol. Eur. J. Pharm. Biopharm., 2008, 69(3), 986-992.
[http://dx.doi.org/10.1016/j.ejpb.2008.02.016] [PMID: 18396020]
[127]
Ito, Y.; Maeda, A.; Kondo, H.; Iwao, Y.; Noguchi, S.; Itai, S. Application of water-insoluble polymers to orally disintegrating tablets treated by high-pressure carbon dioxide gas. Int. J. Pharm., 2016, 511(1), 10-22.
[http://dx.doi.org/10.1016/j.ijpharm.2016.06.132] [PMID: 27374202]
[128]
Bandari, S.; Mittapalli, R.K.; Gannu, R.; Rao, Y.M. Orodispersible tablets: An overview. Asian J. Pharm., 2008, 1-11.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy